Avacta has a pre-clinical stage biopharmaceutical pipeline of Affimer therapeutic candidates for in-house development and partnering. Our focus is on immuno-oncology (IO), a therapeutic area for which the Affimer technology has several key benefits. Avacta’s lead pre-clinical programme is a PD-L1/LAG-3 single molecule bispecific inhibitor. The second major pre-clinical programme is based on the ground-breaking TMAC platform and is a PD-L1 tumour microenvironment targeted I-DASH inhibitor. Beyond these two main programmes, the company is building a portfolio of I-O antagonists and agonists to support future programmes and partnering.

See our current therapeutics pipeline below: